Single-session breast seed implantation achieves 100% local control at 10 years

Permanent palladium-103 breast seed implantation achieved 100% 10-year local control with no grade ≥3 toxicity in selected early breast cancer.

KEY POINTS

  • This prospective single-institution study included 27 patients treated between 2013 and 2015 with permanent breast seed implantation as accelerated partial breast irradiation. Eligibility was restrictive: age ≥50 years, tumor ≤3 cm, margins ≥2 mm, node-negative ductal invasive carcinoma or DCIS, no lymphovascular invasion, ECOG 0–1, and favorable anatomy for implantation.
  • All patients received a single permanent palladium-103 implant prescribed to 90 Gy. Median tumor size was 0.8 cm, all patients were node-negative with negative margins, and none had HER2-positive disease. Median follow-up reached 10.0 years.
  • Implant dosimetry was consistently high quality: median CTV V100 was 100%, PTV V90 97%, and PTV V100 94%. Median implant size was 64 seeds through 15 needles, with a median PTV volume of 47 cc.
  • At 10 years there were no local recurrences, no distant recurrences, and no breast cancer-related deaths. Overall survival was 96.3% at 5 years and 88.3% at 10 years; all four deaths were unrelated to breast cancer.
  • Acute skin reactions were documented in 7 of 27 patients (25.9%): one Grade 1 and five Grade 2 reactions, with one additional rash considered unrelated to radiation. No Grade ≥3 toxicity occurred.
  • Cosmetic outcomes remained favorable. Excellent or good physician-rated cosmesis remained ≥90% throughout structured follow-up through 5 years; at year 5, among the 10 evaluable patients, 40% were rated excellent and 50% good.
  • The technique relies heavily on procedural accuracy because permanent seeds cannot be optimized after implantation. The modified workflow used general anesthesia, a side-mounted stepper, triple verification of each needle deployment, and immediate day-0 CT dosimetry; however, the small sample, restrictive selection, single-center design, and declining cosmetic follow-up limit broader conclusions.

CLINICAL TAKEAWAY

Permanent breast seed implantation can provide durable control with a true single-session APBI workflow for carefully selected low-risk patients, potentially reducing treatment burden for those facing major travel or logistical barriers. The 10-year results are encouraging but should be viewed as supportive rather than comparative evidence because only 27 patients were treated and no control group was included.

SOURCE

Brachytherapy

Browse more research Suggest a correction